Aldehyde inhibition of antioxidant enzymes in the blood of diabetic patients

• Published in: Journal of diabetes 2016-05, Vol.8 (3), p.398-404
• Main Authors: Lankin, Vadim Z., Konovalova, Galina G., Tikhaze, Alla K., Shumaev, Konstantin B., Belova (Kumskova), Elena M., Grechnikova, Maria A., Viigimaa, Margus
• Format: Article
• Language: English
• Subjects: Aldehydes - pharmacology; Animals; antioxidant enzymes; Antioxidants; Antioxidants - chemistry; Antioxidants - metabolism; carbonyl stress; Case-Control Studies; Cattle; Diabetes; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - enzymology; Enzymes; Erythrocytes - drug effects; Erythrocytes - enzymology; Female; free radical oxidation; Glyoxal - pharmacology; Humans; Hypoglycemic Agents - therapeutic use; Male; Malondialdehyde - pharmacology; Metabolism; metformin; Metformin - therapeutic use; Middle Aged; Zn-superoxide dismutase; 二甲双胍; 抗氧化物酶; 羰基应激; 自由基氧化; 铜; 锌超氧化物歧化酶
• ISSN: 1753-0393; 1753-0407
• DOI: 10.1111/1753-0407.12309

Background The aim of the present study was to examine the effect of aldehyde modification on antioxidant enzyme activity in diabetic patients. Methods The activity of commercially available antioxidant enzymes (catalase, glutathione peroxidase [GPx], and Cu,Zn‐superoxide dismutase [SOD]) was determined in vitro prior to and after aldehyde modification. The activity of erythrocyte Cu,Zn‐SOD was assayed in blood drawn from healthy donors, diabetic patients with decompensated carbohydrate metabolism, and diabetic patients after glucose‐lowering therapy. Results In vitro aldehyde modification had no effect on catalase activity, but diminished GPx and Cu,Zn‐SOD activity. In diabetic patients with decompensated carbohydrate metabolism, glucose‐lowering therapy significantly increased Cu,Zn‐SOD activity, the effect being especially pronounced after administration of metformin. Conclusions It is likely that metformin antagonizes the aldehyde‐induced inhibition of erythrocyte Cu,Zn‐SOD in diabetic patients more effectively than sulfonylurea drugs. 摘要 背景 当前这项研究的目的是在糖尿病患者中调查乙醛变性对抗氧化物酶活性的影响。 方法 在乙醛变性之前以及之后在体外分别测定市售的抗氧化物酶(过氧化氢酶,谷胱甘肽过氧化物酶[GPx]以及铜,锌‐超氧化物歧化酶[Cu,Zn‐SOD])活性。对健康人、糖类代谢失代偿的糖尿病患者以及经过降糖治疗之后的糖尿病患者抽血测定红细胞Cu,Zn‐SOD的活性。 结果 体外的乙醛变性对过氧化氢酶的活性没有影响,但是可以降低GPx与Cu,Zn‐SOD的活性。在糖类代谢失代偿的糖尿病患者中,降糖治疗可以显著增加Cu,Zn‐SOD的活性,患者使用二甲双胍治疗后这种效应特别显著。 结论 在糖尿病患者中,二甲双胍拮抗乙醛诱导的红细胞Cu,Zn‐SOD抑制作用可能会比磺酰脲类药物更有效。